Literature DB >> 3312208

Cyclosporin A and osteonecrosis of the femoral head.

J Landmann1, N Renner, A Gächter, G Thiel, F Harder.   

Abstract

A vascular osteonecrosis has occurred in 5 to 40 per cent of patients who have undergone transplantation of a kidney and generally has been considered to be a complication of the use of corticosteroids. Currently cyclosporin A is in general use for its immunosuppressive property, so that a lower dose of corticosteroids is needed. We analyzed the cases of a series of our patients who underwent transplantation of a kidney in order to find out if our present regimen, using cyclosporin A, influenced the prevalence of osteonecrosis of the femoral head. Of a total of 270 patients, osteonecrosis of the femoral head developed in fifteen of 174 who received conventional immunosuppressive therapy and in only one of ninety-six who received cyclosporin A (p less than 0.05). During the first two months after transplantation, the mean dose of prednisone was approximately 2.5 milligrams per kilogram of body weight per day in the group that received conventional immunosuppressive therapy and approximately 1.1 milligrams per kilogram of body weight per day in the group that received cyclosporin A (p less than 0.001). We concluded that the pathogenesis of the osteonecrosis in patients who underwent transplantation of a kidney was probably related to the higher doses of corticosteroids that were administered.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312208

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  7 in total

1.  Late complications after total hip replacement in renal allograft recipients.

Authors:  J Romero; A Schreiber; U Binswanger
Journal:  Int Orthop       Date:  1994       Impact factor: 3.075

2.  High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus.

Authors:  Takeshi Kuroda; Naohito Tanabe; Ayako Wakamatsu; Chinatsu Takai; Hiroe Sato; Takeshi Nakatsue; Yoko Wada; Masaaki Nakano; Ichiei Narita
Journal:  Clin Rheumatol       Date:  2015-09-18       Impact factor: 2.980

3.  Pitavastatin may reduce risk of steroid-induced osteonecrosis in rabbits: a preliminary histological study.

Authors:  Kenjiro Nishida; Takuaki Yamamoto; Goro Motomura; Seiya Jingushi; Yukihide Iwamoto
Journal:  Clin Orthop Relat Res       Date:  2008-03-19       Impact factor: 4.176

4.  Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head.

Authors:  Deike Varoga; Wolf Drescher; Melanie Pufe; Godo Groth; Thomas Pufe
Journal:  Clin Orthop Relat Res       Date:  2009-12       Impact factor: 4.176

5.  Incidence and predictors of osteonecrosis among cyclosporin- or tacrolimus-treated renal allograft recipients.

Authors:  Masaki Takao; Takashi Sakai; Takashi Nishii; Hideki Yoshikawa; Shiro Takahara; Nobuhiko Sugano
Journal:  Rheumatol Int       Date:  2009-10-28       Impact factor: 2.631

6.  The immune reaction to heterologous serum causes osteonecrosis in rabbits.

Authors:  M Matsui; K Ohzono; N Nakamura; N Sugano; K Masuhara; K Nakata; K Takaoka; K Ono; T Ochi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Transitional changes in the incidence of hip osteonecrosis among renal transplant recipients.

Authors:  Masaki Takao; Hirohito Abe; Takashi Sakai; Hidetoshi Hamada; Shiro Takahara; Nobuhiko Sugano
Journal:  J Orthop Sci       Date:  2019-07-04       Impact factor: 1.601

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.